LIPTRUZET (ezetimibe/atorvastatin), fixed combination of cholesterol-lowering drugs
CARDIOLOGY - New medicinal product
Opinions on drugs - Posted on Feb 29 2016
Reason for request
- LIPTRUZET has a Marketing Authorisation, as adjunctive therapy to diet, in adults with hypercholesterolaemia (heterozygous or homozygous familial, or non-familial) or mixed dyslipidaemia when the ezetimibe + atorvastatin combination is indicated.
- The efficacy of the combination (free or fixed) of ezetimibe with atorvastatin has been demonstrated only on a biological criterion, the reduction of LDL cholesterol (LDL-c) levels.
- The efficacy in terms of morbidity and mortality has not been demonstrated to date.
- No clinical data studying the efficacy of the fixed combination is currently available.
Clinical Added Value
|no clinical added value||
Évaluation des médicaments